Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sorrento Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04885972CT.gov Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis | — | Unknown | — | — | — |
NCT04386980CT.gov Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed | — | Withdrawn | — | — | — |
NCT04044742CT.gov A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee | — | Withdrawn | — | — | — |
NCT02566564CT.gov Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis, Knee
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Resiniferatoxin (this asset) | Sorrento Therapeutics, Inc. | P3 | BB · 66 |
| Duloxetine | Orthopaedic Arthroscopy Knee and Shoulder Clinic | P4 | BBB |
| Naproxen | Pfizer | P3 | BB |
| Dexmedetomidine | Poznan University of Medical Sciences | P4 | BB |
| Remimazolam | Seoul National University Hospital | P4 | BB |
| Dextrose Solution | Kastamonu University | P4 | BB |
| Dexasone | Poznan University of Medical Sciences | P4 | BB |
| Triamcinolone Hexacetonide | Kastamonu University | P4 | BB |
| Celecoxib | Pfizer | P4 | BB |
+40 more in the Osteoarthritis, Knee cohort
Other indications for Resiniferatoxin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Morton Neuroma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Resiniferatoxin in Osteoarthritis, Knee. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/resiniferatoxin-osteoarthritis-knee
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →